218 related articles for article (PubMed ID: 25917051)
41. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study.
Fouache D; Goëb V; Massy-Guillemant N; Avenel G; Bacquet-Deschryver H; Kozyreff-Meurice M; Ménard JF; Muraine M; Savoye G; Le Loët X; Tharasse C; Vittecoq O
Rheumatology (Oxford); 2009 Jul; 48(7):761-4. PubMed ID: 19395543
[TBL] [Abstract][Full Text] [Related]
42. Novel agents in the future: Therapy beyond anti-TNF agents in inflammatory bowel disease.
Peng JC; Shen J; Ran ZH
J Dig Dis; 2014 Nov; 15(11):585-90. PubMed ID: 25251263
[TBL] [Abstract][Full Text] [Related]
43. Sustained improvement in health-related quality of life measures in patients with inflammatory bowel disease receiving prolonged anti-tumor necrosis factor therapy.
Sherman M; Tsynman DN; Kim A; Arora J; Pietras T; Messing S; St Hilaire L; Yoon S; Decross A; Shah A; Saubermann L
J Dig Dis; 2014 Apr; 15(4):174-9. PubMed ID: 24373601
[TBL] [Abstract][Full Text] [Related]
44. Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
Danese S
Dig Liver Dis; 2008 Jul; 40 Suppl 2():S225-8. PubMed ID: 18598993
[TBL] [Abstract][Full Text] [Related]
45. Paradoxical immune-mediated inflammation in inflammatory bowel disease patients receiving anti-TNF-α agents.
Fiorino G; Danese S; Pariente B; Allez M
Autoimmun Rev; 2014 Jan; 13(1):15-9. PubMed ID: 23777821
[TBL] [Abstract][Full Text] [Related]
46. Systematic review: antibodies and anti-TNF-α levels in inflammatory bowel disease.
Chaparro M; Guerra I; Muñoz-Linares P; Gisbert JP
Aliment Pharmacol Ther; 2012 May; 35(9):971-86. PubMed ID: 22443153
[TBL] [Abstract][Full Text] [Related]
47. Infliximab therapy for patients with inflammatory bowel disease: 10 years on.
Van Assche G; Vermeire S; Rutgeerts P
Eur J Pharmacol; 2009 Nov; 623 Suppl 1():S17-25. PubMed ID: 19837056
[TBL] [Abstract][Full Text] [Related]
48. [Biological treatments in pediatric IBD].
Svensson M; Lindberg E; Ludvigsson JF
Lakartidningen; 2017 Feb; 114():. PubMed ID: 28245034
[TBL] [Abstract][Full Text] [Related]
49. Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.
Braun J; Baraliakos X; Listing J; Davis J; van der Heijde D; Haibel H; Rudwaleit M; Sieper J
Arthritis Rheum; 2007 May; 57(4):639-47. PubMed ID: 17471540
[TBL] [Abstract][Full Text] [Related]
50. Update on anti-tumor necrosis factor agents and other new drugs for inflammatory bowel disease.
Cohen BL; Sachar DB
BMJ; 2017 Jun; 357():j2505. PubMed ID: 28630047
[TBL] [Abstract][Full Text] [Related]
51. Miscellaneous adverse events with biologic agents (excludes infection and malignancy).
Feuerstein JD; Cheifetz AS
Gastroenterol Clin North Am; 2014 Sep; 43(3):543-63. PubMed ID: 25110258
[TBL] [Abstract][Full Text] [Related]
52. Use of systemic medication in patients with oral lichen planus - a possible association with hypothyroidism.
Robledo-Sierra J; Mattsson U; Jontell M
Oral Dis; 2013 Apr; 19(3):313-9. PubMed ID: 22943671
[TBL] [Abstract][Full Text] [Related]
53. Th1/Th2 cytokine ratio in tissue transudates from patients with oral lichen planus.
Rhodus NL; Cheng B; Ondrey F
Mediators Inflamm; 2007; 2007():19854. PubMed ID: 17497029
[TBL] [Abstract][Full Text] [Related]
54. Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease.
de Bruyn M; Machiels K; Vandooren J; Lemmens B; Van Lommel L; Breynaert C; Van der Goten J; Staelens D; Billiet T; De Hertogh G; Ferrante M; Van Assche G; Vermeire S; Opdenakker G; Schuit F; Rutgeerts P; Arijs I
Inflamm Bowel Dis; 2014 Feb; 20(2):339-52. PubMed ID: 24378596
[TBL] [Abstract][Full Text] [Related]
55. Clinical use and mechanisms of infliximab treatment on inflammatory bowel disease: a recent update.
Guo Y; Lu N; Bai A
Biomed Res Int; 2013; 2013():581631. PubMed ID: 23484133
[TBL] [Abstract][Full Text] [Related]
56. Optimization of anti-TNF therapy in patients with Inflammatory Bowel Disease.
Strik AS; Bots SJ; D'Haens G; Löwenberg M
Expert Rev Clin Pharmacol; 2016; 9(3):429-39. PubMed ID: 26681400
[TBL] [Abstract][Full Text] [Related]
57. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
[TBL] [Abstract][Full Text] [Related]
58. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
[TBL] [Abstract][Full Text] [Related]
59. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
[TBL] [Abstract][Full Text] [Related]
60. Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.
Billioud V; Ford AC; Tedesco ED; Colombel JF; Roblin X; Peyrin-Biroulet L
J Crohns Colitis; 2013 Dec; 7(11):853-67. PubMed ID: 23523418
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
